Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for PACAP-38 Induced Migraine Prevention
NCT02542605Phase 1Completed
- Sponsor
- Amgen
- Start
- Nov 2015
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of erenumab in migraine (3 arms), sponsored by Amgen. Primary endpoint: Number of Participants With a Migraine-like Attack (MLA) Within 24 Hours of Challenge Agent Infusion. Started Nov 2015; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02542605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542605.